/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.
I-Mab (NASDAQ:IMAB – Get Rating) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $15.12 and last traded at $15.12, with a volume of 2 shares. The stock had previously closed at $16.76. A number of equities research analysts have recently commented on IMAB shares. Zacks […]
I-Mab (NASDAQ:IMAB – Get Rating) gapped down before the market opened on Thursday . The stock had previously closed at $21.49, but opened at $19.60. I-Mab shares last traded at $18.63, with a volume of 7,796 shares traded. A number of brokerages have recently weighed in on IMAB. Zacks Investment Research cut shares of I-Mab […]
/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.
/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.